Data Bytes: preclinical IPO performance trending up

The last 18 months have seen a trend towards positive aftermarket performance for preclinical IPOs

IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged.

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE